Street View: Investor focus still on Amgen's weight-loss drug candidate

Amgen AMGN.O said on Thursday its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to speculate on the impact of U.S. tariffs, tax policy would be a more effective way to influence U.S. manufacturing

Median PT of brokerages covering the stock is $315.46 - data compiled by LSEG

FOCUS REMAINS ON MARITIDE

Mizuho ("Neutral", PT: $235) believes many questions remain unanswered on experimental weight-loss drug MariTide, viewed by many investors as a potential blockbuster

J.P.Morgan ("Neutral", PT: $283.78) expects shares to "remain range bound pending longer-term obesity updates for MariTide"

RBC Capital Markets ("Outperform", PT: $320) believes greater visibility into critical inflection points for Horizon-derived products in the rare disease space, like thyroid eye disease drug Tepezza, gout treatment Krystexxa, and immune disorder drug Uplizna is necessary to bolster investor confidence

Piper Sandler ("Overweight", PT: $329) says Amgen's strategy of launching new biosimilars will help in "cushioning the impact" by offsetting the revenue loss from products losing their patent protection

Citi ("Neutral", PT: $300) says they are positive of AMGN's rare product portfolio from the Horizon acquisition